Nuvisertib

TP-3654 · Sumitomo Pharma America, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nuvisertib, covering 2026-04-14 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis [Phase 1, Phase 2]